AR050297A1 - Hidantoinas sustituidas - Google Patents
Hidantoinas sustituidasInfo
- Publication number
- AR050297A1 AR050297A1 ARP050103440A ARP050103440A AR050297A1 AR 050297 A1 AR050297 A1 AR 050297A1 AR P050103440 A ARP050103440 A AR P050103440A AR P050103440 A ARP050103440 A AR P050103440A AR 050297 A1 AR050297 A1 AR 050297A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- alkyl
- alkoxy
- compounds
- Prior art date
Links
- 150000001469 hydantoins Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000005415 substituted alkoxy group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60217504P | 2004-08-17 | 2004-08-17 | |
| US68299705P | 2005-05-20 | 2005-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR050297A1 true AR050297A1 (es) | 2006-10-11 |
Family
ID=35589619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050103440A AR050297A1 (es) | 2004-08-17 | 2005-08-16 | Hidantoinas sustituidas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7427635B2 (enExample) |
| EP (1) | EP1781649B1 (enExample) |
| JP (1) | JP4927733B2 (enExample) |
| KR (2) | KR20090006885A (enExample) |
| AR (1) | AR050297A1 (enExample) |
| AT (1) | ATE404556T1 (enExample) |
| AU (1) | AU2005274390B2 (enExample) |
| BR (1) | BRPI0514515A (enExample) |
| CA (1) | CA2576599A1 (enExample) |
| DE (1) | DE602005008986D1 (enExample) |
| ES (1) | ES2313389T3 (enExample) |
| MX (1) | MX2007001846A (enExample) |
| PL (1) | PL1781649T3 (enExample) |
| RU (1) | RU2383542C2 (enExample) |
| TW (1) | TW200621764A (enExample) |
| WO (1) | WO2006018188A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200621766A (en) * | 2004-09-17 | 2006-07-01 | Hoffmann La Roche | Substituted hydantoins |
| US7612212B2 (en) | 2006-02-22 | 2009-11-03 | Hoffmann-La Roche Inc. | Substituted hydantoins |
| CA2686756A1 (en) * | 2007-05-11 | 2008-11-20 | F. Hoffmann-La Roche Ag | Pharmaceutical compositions for poorly soluble drugs |
| ATE551336T1 (de) | 2007-08-16 | 2012-04-15 | Hoffmann La Roche | Substituierte hydantoine |
| BRPI0820696A2 (pt) * | 2007-12-20 | 2019-09-24 | Hoffmann La Roche | hidantoínas substituídas como inibidores de cinase de mek |
| WO2010074776A2 (en) | 2008-06-16 | 2010-07-01 | The University Of Tennessee Research Foundation | Compounds for the treatment of cancer |
| US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
| US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| JP5651125B2 (ja) | 2008-12-10 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異 |
| WO2011000945A2 (en) * | 2009-07-03 | 2011-01-06 | Nensius Research A/S | Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns |
| ES2576061T3 (es) | 2010-02-25 | 2016-07-05 | Dana-Farber Cancer Institute, Inc. | Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF |
| WO2011109059A1 (en) | 2010-03-01 | 2011-09-09 | Gtx, Inc. | Compounds for treatment of cancer |
| MX343368B (es) | 2010-03-09 | 2016-11-01 | The Broad Inst Inc * | Metodo de diagnostico y tratamiento de cancer en pacientes que tienen o desarrollan resistencia a una primera terapia de cancer. |
| KR20130100903A (ko) | 2010-04-28 | 2013-09-12 | 바이엘 크롭사이언스 아게 | 살진균제로서의 케토헤테로아릴피페리딘 및 케토헤테로아릴피페라진 유도체 |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| MX2021002456A (es) * | 2018-09-17 | 2021-06-15 | Yungjin Pharmaceutical Co Ltd | Nuevos derivados de tiazol y sus sales farmaceuticamente aceptables. |
| JP2023517106A (ja) * | 2020-03-13 | 2023-04-21 | ユンジン ファーム．カンパニー、リミテッド | チアゾール誘導体またはその薬学的に許容される塩を含む癌の予防または治療用薬学組成物 |
| WO2021182914A1 (ko) * | 2020-03-13 | 2021-09-16 | 영진약품 주식회사 | 신규한 cdk7 억제 화합물 및 이의 약제학적으로 허용가능한 염 |
| KR20210146144A (ko) | 2020-05-26 | 2021-12-03 | 엘지전자 주식회사 | 카트부 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770573A (en) * | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
| JP2002511092A (ja) | 1997-07-01 | 2002-04-09 | ワーナー−ランバート・コンパニー | ４−ブロモまたは４−ヨードフェニルアミノベンズヒドロキサム酸誘導体およびそのｍｅｋ阻害剤としての使用 |
| DE60113247T2 (de) * | 2000-05-03 | 2006-06-22 | F. Hoffmann-La Roche Ag | Hydantoin-enthaltende glucokinase aktivatoren |
| BR0211265A (pt) * | 2001-07-19 | 2004-07-20 | Pharmacia Italia Spa | Derivados de fenilacetamido-tiazol, processo para sua preparação e o seu uso como agentes antitumor |
-
2005
- 2005-08-09 KR KR1020087032084A patent/KR20090006885A/ko not_active Ceased
- 2005-08-09 ES ES05771890T patent/ES2313389T3/es not_active Expired - Lifetime
- 2005-08-09 PL PL05771890T patent/PL1781649T3/pl unknown
- 2005-08-09 EP EP05771890A patent/EP1781649B1/en not_active Expired - Lifetime
- 2005-08-09 KR KR1020077004075A patent/KR100889721B1/ko not_active Expired - Fee Related
- 2005-08-09 AU AU2005274390A patent/AU2005274390B2/en not_active Ceased
- 2005-08-09 CA CA002576599A patent/CA2576599A1/en not_active Abandoned
- 2005-08-09 AT AT05771890T patent/ATE404556T1/de active
- 2005-08-09 WO PCT/EP2005/008633 patent/WO2006018188A2/en not_active Ceased
- 2005-08-09 JP JP2007526351A patent/JP4927733B2/ja not_active Expired - Fee Related
- 2005-08-09 MX MX2007001846A patent/MX2007001846A/es active IP Right Grant
- 2005-08-09 DE DE602005008986T patent/DE602005008986D1/de not_active Expired - Lifetime
- 2005-08-09 RU RU2007109651/04A patent/RU2383542C2/ru not_active IP Right Cessation
- 2005-08-09 BR BRPI0514515-5A patent/BRPI0514515A/pt not_active IP Right Cessation
- 2005-08-11 US US11/202,299 patent/US7427635B2/en not_active Expired - Fee Related
- 2005-08-15 TW TW094127672A patent/TW200621764A/zh unknown
- 2005-08-16 AR ARP050103440A patent/AR050297A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005274390B2 (en) | 2012-01-19 |
| US20060041146A1 (en) | 2006-02-23 |
| ATE404556T1 (de) | 2008-08-15 |
| JP4927733B2 (ja) | 2012-05-09 |
| US7427635B2 (en) | 2008-09-23 |
| ES2313389T3 (es) | 2009-03-01 |
| WO2006018188A2 (en) | 2006-02-23 |
| MX2007001846A (es) | 2007-03-28 |
| AU2005274390A1 (en) | 2006-02-23 |
| WO2006018188A3 (en) | 2006-05-18 |
| CA2576599A1 (en) | 2006-02-23 |
| EP1781649A2 (en) | 2007-05-09 |
| PL1781649T3 (pl) | 2009-01-30 |
| TW200621764A (en) | 2006-07-01 |
| JP2008509950A (ja) | 2008-04-03 |
| EP1781649B1 (en) | 2008-08-13 |
| BRPI0514515A (pt) | 2008-06-10 |
| RU2383542C2 (ru) | 2010-03-10 |
| KR20070034635A (ko) | 2007-03-28 |
| DE602005008986D1 (de) | 2008-09-25 |
| KR100889721B1 (ko) | 2009-03-23 |
| RU2007109651A (ru) | 2008-09-27 |
| KR20090006885A (ko) | 2009-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR050297A1 (es) | Hidantoinas sustituidas | |
| AR051290A1 (es) | Derivados de hidantoina sustituidas | |
| UY38767A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados con braf | |
| AR046186A1 (es) | Compuestos derivados de 1,3,8-triaza-espiro[4.5]decan-4-ona | |
| AR062387A2 (es) | El uso de un compuesto derivado de imidazo[1,2-a] piridina, y un medicamento que lo contiene | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR040476A1 (es) | N-cicloalquil, aril o heteroaril n'-quinolin-2-il alquildiaminas y su uso como antagonistas de mch (hormona concentradora de melanina) | |
| CU20090184A7 (es) | Compuestos amino-heterocíclicos | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| CL2010001486A1 (es) | Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak; composicion farmaceutica; kit farmaceutico; su uso en el tratamiento de enfermedades tales como cancer, diabetes, enfermedad de alzheimer, enfermedad hepatica, trastornos del snc, entre otras. | |
| AR044402A1 (es) | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
| EA200501658A2 (ru) | Производные азаспироалканов в качестве ингибиторов металлопротеаз | |
| AR059590A1 (es) | Inhibidores de quinasa basados en la hidantoina | |
| AR070520A1 (es) | Derivados de azuleno nitrogenados,composiciones farmaceuticas que los contienen,proceso de preparacion y usos de los mismos para tratar trastornos metabolicos y digestivos,entre otros. | |
| AR070828A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| CR6165A (es) | Procedimientos e intermedios para preparar compuestos anticancerosos | |
| AR052887A1 (es) | Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa | |
| AR058379A1 (es) | Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. | |
| AR048789A1 (es) | Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar) | |
| PE20190964A1 (es) | Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica | |
| PE20181853A1 (es) | 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1 | |
| PA8609801A1 (es) | Compuestos para el tratamiento de transtornos neurogenerativos | |
| AR054991A1 (es) | Pteridinas sustituidas y su uso para la preparacion de un medicamento para el tratamiento de enfermedades inflamatorias | |
| AR070910A1 (es) | Derivados de sulfonamida sustituida | |
| AR069795A1 (es) | Hidantoinas sustituidas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |